© Retina2020 | Dreamstime.com
There was a time when eye care specialists could do nothing to stop the advance of age-related macular degeneration. Advances in medical therapy offer the potential of halting the vision loss associated with age-related macular degeneration and, in some instances, restoring lost vision. But what is age-related macular degeneration? And what causes AMD, and how is it best treated? Below, we’ll address all of these questions, looking closely at studies that shed light on the condition.
What Is Age-Related Macular Degeneration, and What Causes AMD?
Age-related macular degeneration, or AMD, affects the center of the retina (the macula) and causes blind spots in central vision, necessary for recognizing faces, reading, driving, and performing other activities of daily living. Some patients with the condition also have trouble seeing in low-light situations, such as driving at night.
Do you want to maintain your senses of taste and smell? Are you looking to enjoy years of better vision and sharper hearing?
Claim your FREE guide on medical problems of the eyes, ears, nose, and throat.
Forms of AMD
What is age-related macular degeneration? It encompasses two types:
- Neovascular (“wet”), which occurs when abnormal blood vessels form in the retina and leak fluid that damages the macula. Wet age-related macular degeneration is responsible for about 90 percent of AMD-related blindness.
- Atrophic (“dry”), a breakdown of the macula in which yellow deposits known as drusen accumulate. Although it accounts for most age-related macular degeneration cases, dry AMD usually does not cause legal blindness (defined as visual acuity of 20/200 or less); however, it can progress to a severe form known as geographic atrophy, or to wet AMD.
A Shot of Vision Improvement for Wet AMD Patients
In 2006, the U.S. Food and Drug Administration (FDA) approved ranibizumab (Lucentis), which was shown to stabilize vision and, in some patients, restore some vision lost to wet AMD. The drug, injected directly into the eye, inhibits vascular endothelial growth factor (VEGF), a substance that stimulates the development of abnormal blood vessels in the retina. In 2011, another anti-VEGF drug, aflibercept (Eylea), gained FDA approval for treating wet AMD.
A similar anti-VEGF drug, bevacizumab (Avastin)—designed to prevent cancer-related blood-vessel growth—has been widely used “off-label” to treat wet AMD.
FYIHOW YOU CAN HELP YOUR EYES
In light of the potential improvements afforded by today’s treatments, it’s vital to recognize and treat age-related macular degeneration (AMD) as early as possible. So, have a dilated eye exam every year, or more frequently if your doctor recommends it. See your eyecare professional immediately if you notice any AMD symptoms.
If you have AMD, talk to your doctor about specialized vitamin formulations that contain zinc and the antioxidants beta-carotene and vitamins C and E. Research suggests that these vitamins may reduce the risk of AMD progression.
In addition, do what you can to limit your risk of developing AMD:
- If you’re a smoker, discuss nicotine replacement, medications, counseling, and other strategies to help you quit. Smoking is a leading AMD risk factor.
- When you’re outdoors, limit your sun exposure, and wear UV-protective sunglasses.
- Work with your physician to control your blood pressure, cholesterol, and other cardiovascular risk factors. Research suggest a link between cardiovascular disease and wet AMD.
- Consume a diet rich in fish high in omega-3 fatty acids—such as salmon and mackerel (at least two servings a week)—and antioxidant-rich green leafy vegetables.
Test Results: Hope Lies Ahead
In the Comparison of AMD Treatments Trial (CATT), researchers compared bevacizumab and ranibizumab treatment in nearly 650 people with wet AMD. The drugs performed similarly: After two years, two-thirds of the study participants achieved 20/40 vision or better.
In follow-up findings (Ophthalmology, August 2016), researchers reported that, although the vision improvements gained during the first two years were not maintained after five years of treatment, half the study participants still had 20/40 vision or better. Only one in five had progressed to 20/200 vision or worse. The study also found that the drugs worked about equally as well whether they were administered monthly or on an as-needed basis.
“When we first treat neovascular AMD patients, after they’ve noticed some initial vision loss, they typically gain about two lines worth of visual acuity on the eye chart, and what we’ve seen in this study is that between year two and about year five of anti-VEGF treatment, they lose most of that improvement,” study principal investigator Maureen G. Maguire, PhD, of the University of Pennsylvania’s Perelman School of Medicine, said in a statement. “On the other hand, if they had been untreated, they never would have seen any improvement at all—their vision would have gotten worse and worse.
“The good news is that patients are having much better visual outcomes than even dreamed about 10 years ago,” she added, “but there’s still a considerable proportion of patients for whom long-term outcomes are not good, and we need better treatments for them.”
Researchers continue to study anti-VEGF treatments for wet AMD as well as investigational drugs (such as lampalizumab) for patients with dry AMD. Some preliminary research suggests that lampalizumab may reduce the progression of geographic atrophy. A major clinical trial investigating the safety and efficacy of the injectable drug is ongoing.
Originally published in 2017, this post is regularly updated.